Incannex Healthcare Limited
IHL.AX
Australian Securities Exchange0.04
AUD
+0.00
- -
Incannex Healthcare Limited
IHL.AX
(Australian Securities Exchange)
Recent
price
0.04
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Incannex Healthcare Limited (ASX: IHL) is a clinical-stage biopharmaceutical company focused on the development of cannabinoid medicines and psychedelic derivatives for treating unmet medical needs in inflammation, pain, and mental health disorders. The company offers a pipeline of investigational products including IHL-42X, a fixed-dose combination of ibudilast and THC/CBD for the treatment of obstructive sleep apnea; IHL-675A, a synthetic psilocybin analog targeting anxiety and depression associated with life-threatening illnesses; and other candidates such as IHL-553 for inflammatory conditions, alongside proprietary formulations in pain management and dermatology; it also provides contract research services through its subsidiary facilities. Headquartered in Melbourne, Australia, Incannex was founded in 2018 and operates primarily in Australia with clinical trials and partnerships extending to the United States and Europe, targeting pharmaceutical markets in respiratory, neurological, and psychiatric segments. Recent major developments include the successful completion of Phase 2 trials for IHL-42X in 2024, advancing toward Phase 3 studies; a strategic merger with Catylix, Inc. in early 2025 to bolster its psychedelic drug portfolio; and new funding rounds exceeding AUD 20 million to support expanded U.S. operations and regulatory submissions.